A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening

Journal of Cellular Physiology

Volumn 229, Issue 2, 2014, Pages 148-152

  Romano, Gaetano ^a   Morales, Fátima ^a   Marino, Ignazio R ^a,b   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD30 ANTIGEN; CD9 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 3; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOTRANSPLANTATION; CELL DIFFERENTIATION; DRUG SCREENING; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HUMAN; MULTIPLE SCLEROSIS; MUTAGENESIS; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC CELL; STEM CELL TRANSPLANTATION;

DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84886260596     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24437     Document Type: Review

References (72)

1. Bar-Nur O, Russ HA, Efrat S, Benvenisty N. 2011. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9:17-23.
2. Beachy PA, Karhadkar SS, Berman DM. 2004. Tissue repair and stem cell renewal in carcinogenesis. Nature 432:324-331.
3. Ben-David U, Benvenisty N. 2011. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11:268-277.
4. Bernhardt M, Galach M, Novak D, Utikal J. 2012. Mediators of induced pluripotency and their role in cancer cells-Current scientific knowledge and future perspectives. Biotechnol J 7:810-821.
5. Brickman JM, Burdon TG. 2002. Pluripotency and tumorigenicity. Nat Genet 32:557-558.
6. Chamberlain SJ, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, Lalande M. 2010. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci USA 107:17668-17673.
7. Chipman PH, Toma JS, Rafuse VF. 2012. Generation of motor neurons from pluripotent stem cells. Prog Brain Res 201:313-331.
8. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, He L. 2011. miR-34 miRNA provide a barrier for somatic cell reprogramming. Nat Cell Biol 13:1353-1360.
9. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O. 2012. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4:141ra90.
10. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T. 2011. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 2:440.
11. Fong CY, Gauthaman K, Bongso A. 2010. Teratomas from pluripotent stem cells: A clinical hurdle. J Cell Biochem 111:769-781.
12. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, Nagy A, Wrana JL, Blencowe BJ. 2011. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 147:132-146.
13. Graveley BR. 2011. Splicing up pluripotency. Cell 147:22-24.
14. Giordano A, Fucito A, Romano G, Marino IR. 2007. Carcinogenesis and environment: The cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front Biosci 12:3475-3482.
15. Hartfield EM, Fernandes HJ, Vowles J, Cowley SA, Wade-Martins R. 2012. Cellular reprogramming: A new approach to modelling Parkinson's disease. Biochem Soc Trans 40:1152-1157.
16. Hug K, Hermerén G. 2011. Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Rev 7:761-774.
17. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. 2012. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482:216-2120.
18. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. 2011. Modeling the long QT syndrome with induced pluripotent stem cells. Nature 471:225-229.
19. Kaye JA, Finkbeiner S. 2013. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 56C:50-64.
20. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467:285-290.
21. Ladewig J, Koch P, Brüstle O. 2013. Leveling Waddington: The emergence of direct programming and the loss of cell fate hierarchies. Nat Rev Mol Cell Biol 14:225-236.
22. Lewitzky M, Yamanaka S. 2007. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol 18:467-473.
23. Malik N, Rao MS. 2013. A review of the methods for human iPSC derivation. Methods Mol Biol 997:23-33.
24. Mikkers H, Pike-Overzet K, Staal FJ. 2012. Induced pluripotent stem cells and severe combined immunodeficiency: Merely disease modeling or potentially a novel cure? Pediatr Res 71:427-432.
25. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Goedel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A, Laugwitz KL. 2010. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363:1397-1409.
26. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. 2008. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26:101-106.
27. Nostro MC, Keller G. 2012. Generation of beta cells from human pluripotent stem cells: Potential for regenerative medicine. Semin Cell Dev Biol 23:701-710.
28. Okano H. 2012. Investigation of pathophysiology of Parkinson's disease using iPS cells technology. Rinsho Shinkeigaku 52:899.
29. Ordonez MP, Goldstein LS. 2012. Using human-induced pluripotent stem cells to model monogenic metabolic disorders of the liver. Semin Liver Dis 32:298-306.
30. Parsons XH, Teng YD, Snyder EY. 2009. Important precautions when deriving patient-specific neural elements from pluripotent cells. Cytotherapy 11:815-824.
31. Paşca SP, Portmann T, Voineagu I, Yazawa M, Shcheglovitov A, Paşca AM, Cord B, Palmer TD, Chikahisa S, Nishino S, Bernstein JA, Hallmayer J, Geschwind DH, Dolmetsch RE. 2011. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 17:1657-1662.
32. Peitz M, Jungverdorben J, Brüstle O. 2013. Disease-specific iPS cell models in neuroscience. Curr Mol Med 13:832-841.
33. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. 2010. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28:848-855.
34. Pfisterer U, Wood J, Nihlberg K, Hallgren O, Bjermer L, Westergren-Thorsson G, Lindvall O, Parmar M. 2011. Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle 10:3311-3316.
35. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, Aubry L, Vanti WB, Moreno H, Abeliovich A. 2011. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 146:359-371.
36. Rao M, Condic ML. 2008. Alternative sources of pluripotent stem cells: Scientific solutions to an ethical dilemma. Stem Cells Dev 17:1-10.
37. Reya T, Clevers H. 2005. Wnt signaling in stem cells and cancer. Nature 434:843-850.
38. Roelandt P, Vanhove J, Verfaillie C. 2013. Directed differentiation of pluripotent stem cells to functional hepatocytes. Methods Mol Biol 997:141-147.
39. Romano G. 2004. Stem cell transplantation therapy: Controversy over ethical issues and clinical relevance. Drug News Perspect 17:637-645.
40. Romano G. 2005. The role of adult stem cells in carcinogenesis. Drug News Perspect 18:555-559.
41. Romano G. 2008. Artificial reprogramming of human somatic cells to generate pluripotent stem cells: A possible alternative to the controversial use of human embryonic stem cells. Drug News Perspect 21:440-445.
42. Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A. 2009. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: Implications for the design of safer gene-based interventions in patients. Drug News Perspect 22:185-196.
43. Romano G. 2011. The standpoint of stem cell research: A report on the ninth annual meeting of the International Society for Stem Cell Research. Drugs Future 36:729-732.
44. Rosenzweig A. 2010. Illuminating the potential of pluripotent stem cells. N Engl J Med 363:1471-1472.
45. Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA, Rice CM, Bhatia SN. 2012. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 109:2544-2548.
46. Sekiya S, Suzuki A. 2011. Direct conversion of mouse fibroblasts to hepatocyte- like cells by defined factors. Nature 475:390-393.
47. Semi K, Matsuda Y, Ohnishi K, Yamada Y. 2013. Cellular reprogramming and cancer development. Int J Cancer 132:1240-1248.
48. Shtrichman R, Germanguz I, Itskovitz-Eldor J. 2013. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine. Curr Mol Med 13:792-805.
49. Simara P, Motl JA, Kaufman DS. 2013. Pluripotent stem cells and gene therapy. Transl Res 161:284-292.
50. Singh AM, Reynolds D, Cliff T, Ohtsuka S, Mattheyses AL, Sun Y, Menendez L, Kulik M, Dalton S. 2012. Signaling network crosstalk in human pluripotent cells: A Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10:312-326.
51. Son EY, Ichida JK, Waingler BJ, Toma JS, Rafuse VF, Woolf CJ, Eggan K. 2011. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9:205-218.
52. Song B, Sun G, Herszfeld D, Sylvain A, Campanale NV, Hirst CE, Caine S, Parkington HC, Tonta MA, Coleman HA, Short M, Ricardo SD, Reubinoff B, Bernard CC. 2012. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res 8:259-273.
53. Subba Rao M, Sasikala M, Nageshwar Reddy D. 2013. Thinking outside the liver: Induced pluripotent stem cells for hepatic applications. World J Gastroenterol 19:3385-3396.
54. Swenson ES. 2012. Direct conversion of mouse fibroblasts to hepatocyte-like cells using forced expression of endodermal transcription factors. Hepatology 55:316-318.
55. Szabo E, Rampalli S, Risueño RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-Martin M, Bhatia M. 2010. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468:521-526.
56. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. 2005. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26:495-502.
57. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
58. Takeuchi JK, Bruneau BG. 2009. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 459:708-711.
59. Tang C, Lee AS, Volkmer JP, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Pera RR, Behr B, Wu JC, Weissman IL, Drukker M. 2011. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29:829-834.
60. Tavernier G, Mlody B, Demeester J, Adjaye J, De Smedt SC. 2013. Current methods for inducing pluripotency in somatic cells. Adv Mater 25:2765-2771.
61. Thomson SR, Wishart TM, Patani R, Chandran S, Gillingwater TH. 2012. Using induced pluripotent stem cells (iPSC) to model human neuromuscular connectivity: Promise or reality? J Anat 220:122-130.
62. Tiscornia G, Vivas EL, Belmonte JC. 2011. Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat Med 17:1570-1576.
63. Vierbuchen T, Werning M. 2011. Direct lineage conversions: Unnatural but useful? Nat Biotechnol 29:892-907.
64. Wang Q, Cooney AJ. 2013. The role of nuclear receptors in embryonic stem cells. Adv Exp Med Biol 786:287-306.
65. Wojda U, Kuznicki J. 2013. Alzheimer's disease modeling: Ups, downs, and perspectives for human induced pluripotent stem cells. J Alzheimers Dis 34:563-588.
66. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N. 2011. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 20:4530-4539.
67. Yamanaka S. 2007. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1:39-49.
68. Young JE, Goldstein LS. 2012. Alzheimer's disease in a dish: Promises and challenges of human stem cell models. Hum Mol Genet 21:R82-R89.
69. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920.
70. Zacharias DG, Nelson TJ, Mueller PS, Hook CC. 2011. The science and ethics of induced pluripotency: What will become of embryonic stem cells? Mayo Clin Proc 86:634-640.
71. Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J, Mungamuri SK, Rimmelé P, Kennedy M, Sellers R, Landthaler M, Tuschl T, Chi NW, Lemischka I, Keller G, Ghaffari S. 2011. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 13:1092-1099.
72. Zwi-Dantsis L, Gepstein L. 2012. Induced pluripotent stem cells for cardiac repair. Cell Mol Life Sci 69:3285-3299.